最新医学別冊　診断と治療のABC139　リウマチ・膠原病

出版社： 最新医学社
発行日： 2018-10-01
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： リウマチ・膠原病
電子書籍版： 2018-10-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

目次

  • 特集　リウマチ・膠原病

    序論
    眼で見るリウマチ・膠原病

    第１章　総論
    　膠原病の概念と疫学
    　膠原病のゲノム因子と病態
    　どのような臨床症候で膠原病を考えるか?
    　膠原病の検査所見の特徴と実際
    　リウマチ・膠原病の鑑別診断の進め方
    　膠原病治療の進歩と最近の考え方
    　コラム：「育薬」とは？

    第２章　各論
    　関節リウマチ
    　強直性脊椎炎
    　乾癬性関節炎
    　若年性特発性関節炎
    　成人発症Still病
    　リウマチ性多発筋痛症，RS3PE症候群
    　全身性エリテマトーデス
    　抗リン脂質抗体症候群
    　全身性強皮症
    　コラム：β2Glycoprotien I を発見した頃
    　多発性筋炎・皮膚筋炎
    　混合性結合組織病
    　シェーグレン症候群
    　IgG4関連疾患
    　ANCA関連血管炎
    　結節性多発動脈炎
    　高安動脈炎，巨細胞性動脈炎
    　ベーチェット病
    　再発性多発軟骨炎
    　コラム：難病と臨床個人調査票

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 総論

P.25 掲載の参考文献
1) Klemperer P, et al : Diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. JAMA 119 : 331-332, 1942.
 
2) Klemperer P : The concept of collagen diseases. Am J Pathol 26 : 505-519, 1950.
PubMed
3) Ehrlich G E : Landmark perspective, Diffuse collagen disease. JAMA 251 : 1595-1596, 1984.
PubMed
4) Hargraves M M, et al : Presentation of two bone marrow elements : The "tart" cell and the "LE" cell. Proc Staff Meet Mayo Clin 23 : 23-28, 1948.
 
5) Holman H, et al : The reaction of the lupus erythematosus (L. E.) cell factor with deoxyribonucleoprotein of the cell nucleus. J Clin Invest 38 : 2059-2072, 1959.
PubMed
6) Friou G J : Clinical application of lupus serum nucleoprotein reaction using fluorescent antibody technique. J Clin Invest 36 : 890, 1957.
 
7) 難病情報センター特定医療費 (指定難病) 受給者証所持者数 <http://www.nanbyou.or.jp/entry/5354>
 
P.33 掲載の参考文献
1) Gregersen P K, et al : The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 11 : 1205-1213, 1987.
PubMed
2) Raychaudhuri S, et al : Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 44 : 291-296, 2012.
PubMed
3) International HapMap Consortium : A haplotype map of the human genome. Nature 437 : 1299-1320, 2005.
 
4) Hirschhorn J N, et al : Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6 : 95-108, 2005.
PubMed
5) Wellcome Trust Case Control Consortium : Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 : 661-678, 2007.
 
6) Okada Y, et al : Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506 : 376-381, 2014.
PubMed
7) Ram R, et al : Effects of Type 1 Diabetes Risk Alleles on Immune Cell Gene Expression. Genes 8 : E167, 2017.
 
8) Surolia I, et al : Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466 : 243-247, 2010.
PubMed
9) Gregersen P K, et al : Genetics of autoimmune diseases-disorders of immune homeostasis. Nat Rev Genet 7 : 917-928, 2006.
PubMed
10) Ueda H, et al : Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 : 506-511, 2003.
 
11) Kochi Y, et al : A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 37 : 478-485, 2005.
PubMed
12) Yamamoto K, et al : Genetics of rheumatoid arthritis in Asia-present and future. Nat Rev Rheumatol 11 : 375-379, 2015.
PubMed
13) Ishigaki K, et al : Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis. Nat Genet 49 : 1120-1125, 2017.
PubMed
14) Javirre B M, et al : Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 20 : 170-190, 2010.
 
15) Jeffries M A, et al : Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus, Epigenetics 6 : 593-601, 2011.
PubMed
16) Absher D M, et al : Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 9 : e1003678, 2013.
PubMed
17) Hu N, et al : Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 35 : 804-810, 2008.
PubMed
18) Nakano K, et al : DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 72 : 110-117, 2013.
PubMed
19) Karouzakis E, et al : DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 60 : 3613-3622, 2009.
PubMed
20) Dai R, et al : MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 157 : 163-179, 2011.
PubMed
21) Huang W, et al : DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature 528 : 517-522, 2015.
PubMed
P.40 掲載の参考文献
1) Braun J, et al : Clinical Significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. Ann Rheum Dis 69 (7) : 1264-1268, 2010.
PubMed
2) Jennette J C, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (1) : 1-11, 2012.
 
3) Kelly and Firestein's Textbook of Rheumatology, 10e p1513. Table 87-2, Elsevier, 2016.
 
P.46 掲載の参考文献
1) Nishimura K, et al : Meta-analysis : Diagnostic accuracy of anti-CCP antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146 : 797-813, 2007.
PubMed
2) Rantapaa-Dahlqvist S, et al : Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48 : 2741-2749, 2003.
PubMed
P.55 掲載の参考文献
1) Aletaha D, et al : 2010 rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 : 1580-1588, 2010.
PubMed
2) Taylor W, et al : Classification criteria for psoriatic arthritis : development of new criteria from a large international study. Arthritis Rheum 54 : 2665-2673, 2006.
 
3) Rudwaleit M, et al : The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II) : validation and final selection. Ann Rheum Dis 68 : 777-783, 2009.
PubMed
4) Rudwaleit M, et al : The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70 : 25-31, 2011.
PubMed
5) Petri M, et al : Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 : 2677-2686, 2012.
PubMed
6) van den Hoogen F, et al : 2013 classification criteria for systemic sclerosis : an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 : 2737-2747, 2013.
PubMed
7) Lundberg I E, et al : 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 69 : 2271-2282, 2017.
PubMed
8) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
9) Thomas K T, et al : Periodic fever syndrome in children. J Pediatr 135 : 15-21, 1999.
 
10) Miyakis S, et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006.
 
P.61 掲載の参考文献
1) Houssiau F A, et al : Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (8) : 2121-2131, 2002.
 
2) Chan T M, et al : Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343 (16) : 1156-1162, 2000.
 
3) Kurita T, et al : The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 24 (1) : 3-9, 2015.
PubMed
4) Yokogawa N, et al : Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus : A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol 69 (4) : 791-799, 2017.
PubMed
5) Takeuchi T, et al : The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 6 (11) : 644-652, 2010.
PubMed
6) Tanaka Y : Current concepts in the management of rheumatoid arthritis. Korean J Intern Med 31 (2) : 210-218, 2016.
PubMed
7) Fuchs H A, et al : Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16 (5) : 585-591, 1989.
 
8) Lard L R, et al : Early versus delayed treatment in patients with recent-onset rheumatoid arthritis : comparison of two cohorts who received different treatment strategies. Am J Med 111 : 446-451, 2001.
PubMed
9) Hanaoka H, et al : Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. Arthritis Res Ther 19 (1) : 4, 2017.
PubMed
10) Smolen J S, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (1) : 3-15, 2016.
PubMed
11) an Vollenhoven R F, et al : Treat-to-target in systemic lupus erythematosus : recommendations from an international task force. Ann Rheum Dis 73 (6) : 958-967, 2014.
PubMed

第2章 各論

P.72 掲載の参考文献
1) Smolen J S, et al : Rheumatoid arthritis. Nat Rev Dis Primers 4 : 18001, 2018.
PubMed
2) Aletaha D, et al : 2010 rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 : 1580-1588, 2010.
PubMed
3) Felson D T, et al : American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63 : 573-586, 2011.
PubMed
4) Smolen J S, et al : Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis 69 : 631-637, 2010.
PubMed
5) Smolen J S, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 : 3-15, 2016.
PubMed
6) Singh J A, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68 : 1-26, 2015.
PubMed
7) Smolen J S, et al : EULAR recommendations of the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. Ann Rheum Dis 76 : 960-977, 2017.
PubMed
8) 関節リウマチ診療ガイドライン 2014 (編集 : 一般社団法人日本リウマチ学会). メディカルビュー社.
 
9) Smolen J S, et al : Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73 : 3-5, 2014.
PubMed
10) Schett G, et al : Tapering biologic and conventional DMARD therapy in rheumatoid arthritis : current evidence and future directions. Ann Rheum Dis 75 : 1428-1437, 2016.
PubMed
11) Smolen J S, et al : Maintenance, reduction, or withdrawal of etacercept after treatment with etacercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomized controlled trial. Lancet 381 (9870) : 918-929, 2013.
 
12) Kikuchi J, et al : Efficacy and tolerability of six-week dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. Mod Rheumatol 28 : 444-451, 2018.
 
13) Emery P, et al : Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 371 (19) : 1781-1792, 2014.
 
14) Fleischmann R, et al : Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy) : a phase 3b/4, double-blind, head-to-head, randomized controlled trial. Lancet 390 (10093) : 457-468, 2017.
 
15) McHugh J : Rheumatoid arthritis : Baricitinib more effective than adalimumab. Nat Rev Rheuamtol 13 : 197, 2017.
PubMed
P.79 掲載の参考文献
1) Hukuda S, et al : Spondyloarthropathies in Japan : nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. Rheumatol 28 : 554-559, 2001.
PubMed
2) Weiss R J, et al : Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case-control study with 53,108 patients with fracture. J Rheumatol 37 : 2247-2250, 2010.
 
3) van der Linden S, et al : Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 : 361-368, 1984.
PubMed
4) Tada K, et al : Clinical Images : Nonradiographic Axial Spondyloarthritis With Sacroiliitis Detected by Tomosynthesis. Arthritis Rheumatol 69 : 1706, 2017.
PubMed
5) van den Berg R, et al : ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis : results from the SPondyloArthritis Caught Early (SPACE) -cohort and from the Assessment of SpondyloArthritis international Society (ASAS) -cohort. Ann Rheum Dis 72 : 1646-1653, 2013.
PubMed
6) Smolen J S, et al : Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force. Ann Rheum Dis 77 : 3-17, 2018.
PubMed
7) Sieper J, et al : Effect of continuous versus ondemand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine : results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75 : 1438-1443, 2016.
PubMed
8) van der Heijde D, et al : 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76 : 978-991, 2017.
PubMed
9) Haroon N, et al : The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65 : 2645-2654, 2013.
PubMed
10) Baeten D, et al : Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis : a randomised, double-blind, placebo-controlled trial. Lancet 382 (9906) : 1705-1713, 2013.
PubMed
P.87 掲載の参考文献
1) Ohara Y, et al : Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol 42 : 1439-1442, 2015.
PubMed
2) Ritchlin C T, et al : Psoriatic arthritis. N Engl J Med 376 : 957-970, 2017.
PubMed
3) FitzGerald O, et al : Concepts of pathogenesis in psoriatic arthritis : genotype determines clinical phenotype. Arthritis Res Ther 17 : 115, 2015.
PubMed
4) Bowes J, et al : Dense genotyping of immunerelated susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun 6 : 6046, 2015.
PubMed
5) Schett G, et al : Enthesitis : from pathophysiology to treatment. Nat Rev Rheumatol 13 : 731-741, 2017.
PubMed
6) Moll J M, et al : Psoriatic arthritis. Semin Arthritis Rheum 3 : 55-78, 1973.
PubMed
7) Taylor W, et al : Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 54 : 2665-2673, 2006.
 
8) Mease P : Measures of psoriatic arthritis : Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 63 (Suppl 11) : S64-S85, 2011.
 
9) Mumtaz A, et al : Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70 : 272-277, 2011.
PubMed
10) Helliwell P S, et al : The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72 : 986-991, 2013.
PubMed
11) Smolen J S, et al : Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force. Ann Rheum Dis 77 : 3-17, 2018.
PubMed
12) Coates L C, et al : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommenddatons for psoriatic arthritis. Arthritis Rheumatol 68 : 1060-1071, 2016.
 
13) Gossec L, et al : European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update. Ann Rheum Dis 75 : 499-510, 2016.
PubMed
P.97 掲載の参考文献
1) Fink CW : Proposal for the development of classification criteria for the idiopathic arthritides of childhood. J Rheumatol 22 : 1566-1569, 1995.
PubMed
2) 日本リウマチ学会小児リウマチ調査検討小委員会 : 若年性特発性関節炎初期診療の手引き (2015年). メディカルレビュー社, 大阪, 2015.
 
3) 武井修治 : 小児慢性特定疾患治療研究事業を利活用した若年性特発性関節炎JIAの二次調査. 小児慢性特定疾患治療研究事業. 平成19年度総括・分担研究報告書 p102-113. 2008.
 
4) Yokota S, et al : Guidance on using tocilizumab for juvenile idiopathic arthritis. Mod Rheumatol 21 : 563-571, 2011.
PubMed
5) Yokota S, et al : Guidehnes on the use of etanercept for juvenile idiopathic arthritis in Japan. Mod Rheumatol 20 : 107-113, 2010.
PubMed
6) Yokota S, et al : Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Mod Rheumatol 22 : 491-497, 2012.
PubMed
P.104 掲載の参考文献
1) Naito T, et al : Diagnostic workup for fever of unknown origin : amulticenter collaborative retrospective study. BMJ Open 3 : e003971, 2013.
 
2) Asanuma Y F, et al : Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 25 : 393-400, 2015.
PubMed
3) Mimura T, et al : Evidence-based clinical practice guideline for adult Still's disease. Mod Rheumatol published online <https://doi.org/10.1080/14397595.2018.1465633>
 
4) Ichida H, et al : Clinical manifestations of Adult-Onset Still's disease presenting with erosive arthritis : Association with low levels of ferritin and interleukin-18. Arthritis Care Res 66 : 642-646, 2014.
PubMed
5) Ravelli A, et al : 2016 Classification Criteria for Macrophage Activation Syndrome complicating Systemic Juvenile Idiopathic Arthritis. A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Ann Rheum Dis 75 : 481-489, 2016.
PubMed
6) Fautrel B, et al : Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26 : 373-378, 1999.
PubMed
7) Mitamura M, et al : Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease. Mod Rheumatol 19 : 57-63, 2009.
 
8) Suematsu R, et al : Therapeutic response of patients with adult Stilrs disease to biologic agents : multicenter results in Japan. Mod Rheumatol 22 : 712-719, 2012.
PubMed
9) Ortiz-Sanjuan F, et al : Efficacy of Tocilizumab in conventional treatment-refractory adult-onset Still's disease. Arthritis Rheumatol 86 : 1659-1665, 2014.
 
10) Schelert G S, et al : Macrophage activation syndrome and cytokine-directed therapies Best Prac Res Clin Rheumatol 28 : 277-292, 2014.
 
11) Jamilloux Y, et al : Pathogenesis of adult-onset Still's disease : new insights from the juvenile counterpart Immunol Res 61 : 53-62, 2015.
PubMed
12) Gabay C, et al : Open-label, multicentre, dose-escalating Phase H clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis 77 : 840-847, 2018.
 
P.117 掲載の参考文献
1) Bruce W : Senile Rheumatic Gout. Br Med J 2 (1450) : 811-813, 1888.
PubMed
2) BARBER H S : Myalgic syndrome with constitutional effects ; polymyalgia rheumatica. Ann Rheum Dis 16 (2) : 230-237, 1957.
PubMed
3) Dejaco C, et al : 2015 Recommendations for the management of polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74 (10) : 1799-1807, 2015.
PubMed
4) Gonzalez-Gay M A, et al : Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61 (10) : 1454-1461, 2009.
PubMed
5) Okumura T, et al : The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int 32 (6) : 1695-1699, 2012.
 
6) Cimmino M A, et al : A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 49 (7) : 521-523, 1990.
PubMed
7) Perfetto F, et al : Seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 64 (11) : 1662-1663, 2005.
PubMed
8) Gonzalez-Gay M A, et al : Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 33 (1) : 38-48, 2003.
PubMed
9) Cimmino M A, et al : Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin Exp Rheumatol 1 (3) : 309-313, 1993.
 
10) Elling P, et al : Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Derlmark ; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 23 (1) : 112-119, 1996.
PubMed
11) Straub R H, et al : The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 39 (6) : 624-631, 2000.
PubMed
12) 西岡淳一, 他 : わが国におけるリウマチ性多発筋痛症 (polymyalgia rheumatica) の病態調査と日本人における診断基準確率の必要性への示唆. リウマチ 25 : 265-273, 1985.
 
13) Bird H A, et al : An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38 (5) : 434-439, 1979.
PubMed
14) Salvarani C, et al : Distal musculoskeletal manifestations in polymyalgia rheumatica : a prospective followup study. Arthritis Rheum 41 (7) : 1221-1226, 1998.
PubMed
15) van der Geest K S, et al : Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford) 54 (8) : 1397-1402, 2015.
PubMed
16) Fukui S, et al : MMP-3 can distinguish isolated PMR from PMR with GCA : A retrospective study regarding PMR and GCA in Japan. Mod Rheumatol 26 (2) : 259-264, 2016.
PubMed
17) Camellino D, et al : Imaging of polymyalgia rheumatica : indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford) 51 (1) : 77-86, 2012.
PubMed
18) Jimenez-Palop M, et al : Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann Rheum Dis 69 (5) : 879-882, 2010.
PubMed
19) Takahashi H, et al : Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol 25 (4) : 546-551, 2015.
PubMed
20) Yamashita H, et al : Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica : evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 22 (5) : 705-711, 2012.
PubMed
21) Blockmans D, et al : Repetitive 18-fluorodeoxy-glucose positron emission tomography in isolated polymyalgia rheumatica : a prospective study in 35 patients. Rheumatology (Oxford) 46 (4) : 672-677, 2007.
 
22) Kreiner F, et al : Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 62 (12) : 3768-3775, 2010.
PubMed
23) Meliconi R, et al : Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 39 (7) : 1199-1207, 1996.
PubMed
24) Gonzalez-Gay M A, et al : Giant cell arteritis and polymyalgia rheumatica : an update. Curr Rheumatol Rep 17 (2) : 6, 2015.
PubMed
25) Kyle V, et al : The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52 (12) : 847-850, 1993.
PubMed
26) Hernandez-Rodriguez J, et al : Treatment of polymyalgia rheumatica : asystematic review. Arch Intern Med 169 (20) : 1839-1850, 2009.
 
27) Devauchelle-Pensec V, et al : Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica : a prospective longitudinal study. Ann Rheum Dis 75 (8) : 1506-1510, 2016.
PubMed
28) Pfeifer E C, et al : Polymyalgia Rheumatica and its Association with Cancer. Rheumatology (Sunnyvale) 2015 : Suppl 6, 2015.
 
29) Muller S, et al : Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis 73 (10) : 1769-1773, 2014.
PubMed
30) Salvarani C, et al : Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (4) : 261-271, 2002.
PubMed
31) Chuang T Y, et al : Polymyalgia rheumatica : a 10-year epidemiologic and clinical study. Ann Intern Med 97 (5) : 672-680, 1982.
PubMed
32) McCarty D J, et al : Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254 (19) : 2763-2767, 1985.
 
33) Russell E B : Remitting seronegative symmetrical synovitis with pitting edema syndrome : followup for neoplasia. J Rheumatol 32 (9) : 1760-1761, 2005.
PubMed
34) Sibilia J, et al : Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) : a form of paraneoplastic polyarthritis? J Rheumatol 26 (1) : 115-120, 1999.
PubMed
35) Arima K, et al : RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64 (11) : 1653-1655, 2005.
PubMed
36) Kawashiri S Y, et al : Monitoring of therapeutic efficacy in a patient with RS3PE syndrome by serologic variables and radiographic methods. Rheumatol Int 30 (12) : 1677-1680, 2010.
 
37) 折口智樹他 : 悪性腫瘍を合併したRS3PE症候群の9例の検討. 九州リウマチ 32 : 206-214, 2012.
 
38) Origuchi T, et al : High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol 22 (4) : 584-588, 2012.
PubMed
39) Olive A, et al : The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE. J Rheumatol 24 (2) : 333-336, 1997.
 
40) 折口智樹, 他 : RS3PE症候群. 免疫症候群 1. 日本臨床社, 東京, 2015.
 
41) Origuchi T, et al : Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Mod Rheumatol 27 (1) : 150-154, 2017.
PubMed
P.128 掲載の参考文献
1) Oku K, et al : Systemic Lupus Erythematosus : nothing stale her infinite variety. Mod Rheumatol (in press)
 
2) Harley I T, et al : Genetic susceptibility to SLE : new insights from fine mapping and genome-wide association studies. Nat Rev Genet 10 : 285-290, 2009.
PubMed
3) Hochberg M C : Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 : 1725, 1997.
PubMed
4) Yokogawa N, et al : Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus : A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol 69 : 791-799, 2017.
PubMed
5) Bertsias G K, et al : Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommerldations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 : 1771-1782, 2012.
 
6) Hahn B H, et al : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. American College of Rheumatology. Arthritis Care Res (Hoboken) 64 : 797-808, 2012.
PubMed
7) Yasuda S, et al : Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. Mod Rheumatol 25 : 854-857, 2015.
PubMed
8) Zhang F, et al : A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77 : 355-363, 2018.
 
9) Dooley M A, et al : Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 : 1886-1895, 2011.
PubMed
10) Furie R A, et al : Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus : A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol 70 : 868-877, 2018.
PubMed
P.133 掲載の参考文献
1) Cervera R, et al : The Euro-Phospholipid project : epidemiology of the antiphospholipid syndrome in Europe. Lupus 18 : 889-893, 2009.
PubMed
2) Forastiero R, et al : Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 17 : 872-877, 2008.
PubMed
3) Galli M, et al : The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 81 : 695-700, 1999.
PubMed
4) Cervera R, et al : Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of diseases expression in a cohort of 1,000 patients. Arthritis Rheum 46 : 1019-1027, 2002.
 
5) Cervera R, et al : Morbidity and mortality in the antiphospholipid syndrome during a 5-year period : a multicenter prospective study of 1000 patients. Ann Rheum Dis 68 : 1428-1432, 2009.
PubMed
6) Schmidt-Tanguy A, et al : Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 11 : 1927-1929, 2013.
PubMed
7) Cervera R, et al : Morbidity and mortality in the antiphospholipid syndrome during a 10-year period : a multicenter prospective study of 1000 patients. Ann Rheum Dis 74 : 1011-1018, 2015.
PubMed
8) Uthman I, et al : The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 22 : 187-194, 2008.
PubMed
9) Zuily S, et al : Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep 15 : 320, 2013.
PubMed
10) Espinosa G, et al : Adrenal involvement in the antiphospholipid syndrome : clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 82 : 106-118, 2003.
PubMed
11) Giannakopoulos B, et al : How we diagnose the antiphospholipid syndrome. Blood 113 : 985-994, 2009.
PubMed
12) Miyakis S, et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006.
 
13) Kaul M, et al : Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66 : 927-930, 2007.
PubMed
14) Ruiz-Irastorza G, et al : Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients : report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20 : 206-218, 2011.
PubMed
15) Pengo V, et al : High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome : 'PROS' and 'CONS'. Autoimmun Rev 11 : 577-580, 2012.
PubMed
16) Lockshin M, et al : Cardiac disease in the antiphospholipid syndrome : recommendations for treatment. Committee consensus report. Lupus 12 : 518-523, 2003.
PubMed
17) Andrade D, et al : 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome treatment trends report. In : Antiphospholipid Syndrome, 1 (Erkan D, et al, Eds), p317. Springer International Publishing, 2017.
 
P.142 掲載の参考文献
1) van den Hoogan F, et al : 2013 classification criteria for systemic sclerosis : an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 (11) : 2737-2747, 2013.
 
2) Kuwana M : Circulating anti-nuclear antibodies in systemic sclerosis : utility in diagnosis and disease subsetting. J Nippon Med Sch 84 (2) : 56-63, 2017.
PubMed
3) Kowal-Bielecka O, et al : Update of EULAR recommendations for the treatment of systemic sclerosis Ann Rheum Dis 76 (8) : 1327-1339, 2017.
PubMed
4) Tashkin D P, et al : Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (25) : 2655-2666, 2006.
PubMed
5) Tashkin D P, et al : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II) : a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4 (9) : 708-719, 2016.
 
6) van Laar J, et al : Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis : a randomized clinical trial J AMA 311 (24) : 2490-2498, 2014.
 
7) 桑名正隆 : 強皮症の新たな治療概念. 臨床リウマチ 27 (4) : 281-287, 2015.
 
8) Koenig M, et al : Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis : a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58 (12) : 3902-3912, 2008.
PubMed
9) 桑名正隆 : 強皮症における分子標的治療の可能性. リウマチ科 55 (3) : 292-297, 2016.
 
P.152 掲載の参考文献
1) Ohta A, et al : Prevalence and inciderlce of polymyositis and dermatomyositis in Japan. Mod Rheumatol 24 : 477-480, 2014.
PubMed
2) Fujimoto M, et al : Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol 28 : 636-644, 2016.
PubMed
3) Lundberg I E, at al : 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76 : 1955-1964, 2017.
 
P.157 掲載の参考文献
1) 三森経世 : 混合性結合組織病の診療ガイドライン (改訂第3版) pp1-64. 厚生労働科学研究費難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班. 2011.
 
2) Sharp G C, et al : Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigens (ENA). Am J Med 52 : 148-159, 1972.
 
3) 粕川禮司 : 混合性結合組織病診断の手引きと治療指針. 厚生省特定疾患混合性結合組織病調査研究班昭和62年度研究報告, P1-515, 1988.
 
P.169 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究班 (研究代表者, 住田孝之) 編 : シェーグレン症候群診療ガイドライン 2017年版. 12 診断と治療社, 東京, 2017.
 
2) Sumida T, et al : Clinical practice guideline for Sjogren's syndrome 2017. Mod Rheumatol 28 : 383-408, 2018.
PubMed
P.177 掲載の参考文献
1) Yamamoto M, et al : Mechanisms and assessment of IgG4-related disease : lessons for the rheumatologist Nat Rev Rheumatol 10 (3) : 148-159, 2014.
PubMed
2) Hamano H, et al : High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344 (10) : 732-738, 2001.
PubMed
3) Takahashi H, et al : The birthday of a new syndrome : IgG4-related diseases constitute a clinical entity. Autoimmun Rev 9 (9) : 591-594, 2010.
PubMed
4) Yamamoto M, et al : Risk of malignancies in IgG4-related disease. Mod Rheumatol 22 (3) : 414-418, 2012.
PubMed
5) Mattoo H, et al : De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134 (3) : 679-687, 2014.
PubMed
6) Shiokawa M, et al Pathogenecity of IgG in patients with IgG4-related disease. Gut 65 (8) : 1322-1332, 2016.
 
7) Watanabe T, et al : Involvement of activation of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum 64 (3) : 914-924, 2012.
PubMed
8) Takano K, et al : A study of infra-orbital nerve swelling associated with immunoglobulin G4 Mikulicz's disease. Mod Rheumatol 24 (5) : 798-801, 2014.
 
9) IgG4関連全身硬化性疾患の診断法の確立と治療方法の開発に関する研究班・新規疾患IgG4関連多臓器リンパ増殖性疾患確立のための研究班 : IgG4関連疾患包括診断基準 2011. 日内会誌 101 (3) : 795-804, 2012.
 
10) Khosroshahi A, et al : International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheum 67 (7) : 1688-1699, 2015.
 
11) 高橋裕樹 : IgG4関連疾患. GUIDELINE膠原病・リウマチ-治療ガイドラインをどう読むか- (小池隆夫, 他Wt), p43-49. 診断と治療社, 東京, 2010.
 
12) Yamamoto M, et al : Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis : Results from the SMART database. Mod Rheumatol 25 (2) : 199-204, 2015.
PubMed
13) Masaki Y, et al : A multicenter phase H prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod Rheumatol 27 (5) : 849-854, 2017.
PubMed
14) Shirakashi M, et al : Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease : a multicentre study. Sci Rep 2018 (in press).
 
15) Pergino A C, et al : IgG4-related disease. Insights into human immunology and targeted therapies. Arthritis Rheum 69 (9) : 1722-1732, 2017.
 
16) Khosroshahi A, et al : Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62 (6) : 1755-1762, 2010.
PubMed
17) Carruthers M N, et al : Rituximab for IgG4-related disease : a prospective, open-label trial. Ann Rheum Dis 74 (6) : 1171-1176, 2015.
PubMed
18) Xiao X, et al : The immunologic paradoxes of IgG4-related disease. Clin Rev Allergy Immunol 54 (2) : 344-351, 2018.
PubMed
P.188 掲載の参考文献
1) Chen M, et al : ANCA-associated vasculitides-advances in pathogenesis and treatment Nat Rev Rheumatol 6 (11) : 653-664, 2010.
PubMed
2) Lyons P A, et al : Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367 (3) : 214-223, 2012.
PubMed
3) Xiao H, et al : Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 (7) : 955-963, 2002.
PubMed
4) Falk R J, et al : Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87 (11) : 4115-4119, 1990.
PubMed
5) Ewert B H, et al : Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 41 (2) : 375-383, 1992.
PubMed
6) Watanabe H, et al : Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis : Subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol 2018 [Epub ahead of printl.
 
7) Csernok E : Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev 2 (3) : 158-164, 2003,
PubMed
8) Halbwachs L, et al : Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol 23 (9) : 1449-1461, 2012.
PubMed
9) Brinkmann V, et al : Neutrophil extracellular traps kill bacteria. Science 303 (5663) : 1532-1535, 2004.
PubMed
10) Kessenbrock K, et al : Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15 (6) : 623-625, 2009.
PubMed
11) Kraaij T, et al : Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int 2018 [Epub ahead of print].
 
12) Nakazawa D, et al : Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol 25 (5) : 990-997, 2014.
PubMed
13) Harabuchi Y, et al : Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV) : A retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 27 (1) : 87-94, 2017.
PubMed
14) Sada K E, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 (2) : R101, 2014.
 
15) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 (2) : 222-227, 2007.
PubMed
16) Robson J C, et al : Draft classification criteria for anca associated vasculitides. EULAR 2018 Abstract#OP0021 <http://ard.bmj.com/content/77/Suppl_2/60.2>
 
17) Ntatsaki E, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53 (12) : 2306-2309, 2014.
PubMed
18) Yates M, et al : EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75 (9) : 1583-1594, 2016.
 
19) Stone J H, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 (3) : 221-232, 2010.
PubMed
20) Jones R B, et al : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (3) : 211-220, 2010.
PubMed
21) ANCA関連血管炎診療ガイドライン 2017. 診断と治療社, 東京, 2017.
 
22) Guillevin L, et al : The Five-Factor Score revisited : assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 (1) : 19-27, 2011.
 
23) Wechsler M E, et al : Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 376 (20) : 1921-1932, 2017.
PubMed
24) Jayne D, et al : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (1) : 36-44, 2003.
PubMed
25) Guillevin L, et al : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 (19) : 1771-1780, 2014.
 
26) Charles P, et al : Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission : results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018 [Epub ahead of print].
 
27) 丸山彰一監 : エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2017. 東京医学社, 東京, 2017.
 
28) PEXIVAS drops at#ERAEDTA18. <http://www.nephjc.com/news/pexivasearly>
 
29) Tsurikisawa N, et al : Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 92 (1) : 80-87, 2004.
PubMed
30) Sada K E, et al : Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Mod Rheumatol 26 (5) : 730-737, 2016.
 
31) Robson J, et al : Damage in the anca-associated vasculitides : long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 74 (1) : 177-184, 2015.
 
P.198 掲載の参考文献
1) 中林公正 : 中・小型血管炎の疫学, 予後, QOLに関する小委員会報告. 難治性血管炎分科会平成10年度研究報告書 (厚生省特定疾患免疫疾患調査研究班) p38-48. 1999.
 
2) Haugeberg G, et al : Primary vasculitis in a Norwegian community hospital : a retrospective study. Clin Rheumatol 17 : 364-368, 1998.
 
3) Arkin A : A Clinical and Pathological Study of Periarteritis Nodosa : A Report of Five Cases, One Histologically Healed. Am J Pathol 6 : 401-426.5, 1930.
 
4) Selga D, et al : Polyarteritis nodosa when applying the Chapel Hill nomenclature-a descriptive study on ten patients. Rheumatology (Oxford) 45 : 1276-1281, 2006.
 
5) Pagnoux C, et al : Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides : analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 84 : 115-128, 2005.
PubMed
6) 川上民裕 : 血管炎と抗リン脂質抗体そして抗LAMP-2抗体. 日皮会誌 123 : 2227-2237, 2013.
 
7) 日本皮膚科学会血管炎・血管障害診療ガイドライン改訂版作成委員会 : 血管炎・血管障害診療ガイドライン 2016年改訂版. 日皮会誌 127 : 299-415, 2017.
 
8) MacLaren K, et al : Primary angiitis of the central nervous system : emerging variants. QJM 98 : 643-654, 2005.
PubMed
9) Teichman J M, et al : Polyarteritis nodosa presenting as acute orchitis : a case report and review of the literature. J Urol 149 : 1139-1140, 1993.
PubMed
10) Steidl C, et al : Vasculitic multiplex mononeuritis : polyarteritis nodosa versus cryoglobulinemic vasculitis. Rheumatol Int 32 : 2543-2546, 2012.
PubMed
11) 日本循環器学会, 他 : 血管炎症候群の診療ガイドライン (2017年改訂版). 2018. <http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf>
 
12) Jayne D : Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13 : 48-55, 2001.
 
13) Ribi C, et al : Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors : A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62 : 1186-1197, 2010.
PubMed
P.206 掲載の参考文献
1) Jennet J C, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (1) : 1-11, 2013.
 
2) 厚生労働省の指定難病ホームページより <https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000062437.html>
 
3) Dagna L, et al : Pentraxin-3 as a Marker of Disease Activity in Takayasu Arteritis. Ann Intern Med 155 (7) : 425-433, 2011.
PubMed
P.216 掲載の参考文献
1) Greco A, et al : Behcet's disease : New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17 : 567-575, 2018.
PubMed
2) Hatemi G, et al : 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis 77 : 808-818, 2018.
PubMed
P.227 掲載の参考文献
1) McAdam L P, et al : Relapsing polychondritis : prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55 (3) : 193-215, 1976.
 
2) Michet C J Jr, et al : Relapsing Polychondritis : survival and predictive role of early disease manifestations. Ann Intern Med 104 (1) : 74-78, 1986.
PubMed
3) Mathian A, et al : Relapsing polychondritis : A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol 30 (2) : 316-333, 2016.
PubMed
4) Kent P D, et al : Relapsing polychondritis. Curr Opin Rheumatol 16 (1) : 56-61, 2004.
PubMed
5) Oka H, et al : Alarge-scale survey of patients with relapsing Polychondritis in Japan. Inflamm Regen 34 : 149-156, 2014.
 
6) Hazra N, et al : Incidence and mortality of relapsing polychondritis in the UK : a population-based cohort study. Rheumatol Oxf 54 (12) : 2181-2187, 2015.
 
7) Lahmer T, et al : Relapsing polychondritis : an autoimmune disease With many faces. Autoimmun Rev 9 (8) : 540-546, 2010.
PubMed
8) Arnaud L, et al : Pathogenesis of relapsing polychondritis a 2013 update. Autoimmun Rev 13 (2) : 90-95, 2014.
PubMed
9) Cremer M A, et al : Auricular chondritis in rats. An experimental model of relapsing polychondritis induced with type II collagen. J Exp Med 154 (2) : 535-540, 1981.
PubMed
10) Taneja V, et al : Auricular chondritis in NOD. DQ & Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis. J Clin Invest 112 (12) : 1843-1850, 2003.
PubMed
11) Lang B, et al : Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 36 (5) : 660-664, 1993.
PubMed
12) Foidart J M, et al : Antibodies to type II collagen in relapsing Polychondritis. N Engl J Med 299 (22) : 1203-1207, 1978.
PubMed
13) Letko E, et al : Relapsing polychondritis : a clinical review. Semin Arthritis Rheum 31 (6) : 384-395, 2002.
PubMed
14) 鈴木知美, 他 : 再発性多発軟骨炎の病態・診断・治療. リウマチ科 56 (4) : 422-430, 2016.
 
15) Shimizu J, et al : Cardiac involvement in relapsing polychondritis in Japan. Rheumatology (Oxford) 55 (3) : 583-584, 2016.
PubMed
16) Suzuki N, et al : Neurological involvement of relapsing polychondritis in Japan : An epidemiological study. Inflamm Regen 34 : 206-208, 2014.
 
17) Mathew S D, et al : Relapsing polychondritis in the Department of Defense population and review of the literature. Semin Arthritis Rheum 42 (1) : 70-83, 2012.
PubMed
18) Shimizu J, et al : Cutaneous manifestations of patients with relapsing polychondritis : an association with extracutaneous complications. Clin Rheumatol 35 (3) : 781-783, 2016.
PubMed
19) Damiani J M, et al : Relapsing Polychondritis. Report of ten cases. Laruygoscope (St. Lous) 89 (6 Pt 1) : 929-946, 1979.
 
20) Arnaud L, et al : The Relapsing polychondritis disease activity index : development of a disease activity score for relapsing Polychondritis. Autoimmun Rev 12 (2) : 204-209, 2012.
PubMed
21) Dion J, et al : Relapsing Polychondritis can be characterized by three different clinical phenotypes. Arthritis Rheumatol 68 (12) : 2992-3001, 2016.
PubMed
22) Shimizu J, et al : Organ involvement pattern suggests subgroups within relapsing polychondritis. Arthritis Rheumatol 70 (1) : 148-149, 2018.
PubMed
23) Kemta Lekpa F, et al : Biologics in relapsing polychondritis : a literature review. Semin Arthritis Rheum 41 (5) : 712-719, 2012.
PubMed
24) McCarthy E M, et al : Treatment of relapsing polychondritis in the era of biological agents. Rheumatol Int 30 (6) : 827-828, 2010.
PubMed
25) Hong G, et al : Clinical characteristics and treatment outcomes of patients with relapsing polychondritis with airway involvement. Clin Rheumatol 32 (9) : 1329-1335, 2013.
PubMed

書評

最近チェックした商品履歴

Loading...